|
|
China Aoxing Given Preferred Status for Cancer Pain Drug
publication date: Nov 27, 2007
China Aoxing Pharmaceutical Company received “designated manufacturer status” for Tilidine, an opioid medication for cancer pain, from the China State Food & Drug Administration. The designation means China Aoxing will have five years of manufacturing exclusivity for Tilidine. Under present rules, China allows only 13 companies to produce narcotic drugs such as Tilidine, and even more important, only one to three companies are permitted to produce the active pharmaceutical ingredients of the medication. The low-risk business plan of China Aoxing is to introduce Western-style pain drugs to China. More details...
Stock Symbol: (OTCBB: CAXG)
|
ChinaBio® Events
ChinaBio® Partnering Forum 2012May 23-24, 2012 Suzhou, China >>More events...
Partner Events
 China Healthcare Investment Conference 2012March 13-15, 2012 Shanghai, China Shanghai CEO ConferenceMarch 28-29, 2012 Shanghai, China >>More details...
Other Events
China Pharmaceutical R&D SummitApril 23-26, 2012 Shanghai, China Biosimilars Asia 2012April 23-26, 2012 Shanghai, China Vaccines China 2012April 23-26, 2012 Shanghai, China
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|